Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Universal Ibogaine Inc ( (TSE:IBO) ) has provided an announcement.
Universal Ibogaine Inc. provided an update regarding its current Cease Trade Order, initially issued due to delays in filing its annual financial documents. These delays were attributed to limited finances and the prolonged sale of a non-core property. The company is now progressing with its audit and plans to complete necessary filings by late February 2025, after which it will seek to lift the cease trade status. This development indicates a potential stabilization in the company’s operations, enabling it to focus on advancing its clinical trial application with Health Canada and resuming its research and development activities.
More about Universal Ibogaine Inc
Universal Ibogaine Inc. is a life sciences company focused on revolutionizing addiction treatment through medicalized ibogaine, particularly targeting opioid use disorder. The company aims to implement this treatment via a planned Canadian clinical trial and future global licensing agreements. Additionally, Universal Ibogaine is developing a comprehensive holistic addiction treatment protocol at the Kelburn Recovery Centre in Manitoba, Canada.
YTD Price Performance: 100.0%
Average Trading Volume: 171,126
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$5.5M
For a thorough assessment of IBO stock, go to TipRanks’ Stock Analysis page.
